2, 4-Diamino-6- hydroxy pyrimidine inhibits NSAIDs induced nitrosyl-complex EPR signals and ulcer in rat jejunum by Somasundaram, S et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Gastroenterology
BMC Gastroenterology  2002,  2 x Research article
2, 4-Diamino-6- hydroxy pyrimidine inhibits NSAIDs induced 
nitrosyl-complex EPR signals and ulcer in rat jejunum
S Somasundaram*1, R Simpson2, S Rafi2, JK Shergill3, I Bjarnason2 and 
J Wrigglesworth3
Address: 1Lineberger Comprehensive Cancer Center, CB#7295, University of North Carolina, Chapel Hill. N.C 27599, 2Departments of Digestive 
Diseases, Kings College Hospital School of Medicine, London SE5 9PJ, UK and 3Centre for the Study of Metals In Biology and Medicine, King's 
College, London, SE1 8WA, UK
E-mail: S Somasundaram* - sivasoma@med.unc.edu; R Simpson - robert.simpson@kcl.ac.uk; S Rafi - sue.rafi@kcl.ac.uk; 
JK Shergill - j.shergill@kcl.ac.uk; I Bjarnason - ingvar.bjarnason@kcl.ac.uk; J Wrigglesworth - john.wrigglesworth@kcl.ac.uk
*Corresponding author
Abstract
Background: It has been suggested that one aspect of non-steroidal anti-inflammatory drugs
induced intestinal damage is due to either uncoupling of mitochondrial oxidative phosphorylation
or inhibition of electron transport. We investigated the latter possibility using electron
paramagnetic resonance spectroscopy.
Results: Electron paramagnetic studies of NSAIDS on sub-mitochondrial particles revealed that
indomethacin, but not with nabumetone, bound to a site near to Complex I and ubiquinone to
generate a radical species. Normal rats exhibited prominent [3Fe-4S]ox signals (g ~ 2.01) at 20 K.
One hour after indomethacin there was a prominent, intense and broad absorption pattern at (g
~2.07) suggesting, appearance of radical species overlapping [3Fe-4S]ox and was unaffected by
pretreatment with 2,4 diamino -6-hydroxy pyrimidine. At 24 hrs, when macroscopic ulcers were
seen, there was a new signal due to a nitric oxide radical (NO•). In contrast, nabumetone and 2,4
diamino-6-hydroxy pyrimidine pre-treated animals receiving indomethacin exhibited electron
paramagnetic resonance spectra identical to those of controls at 24 hrs and neither was associated
with small intestinal ulcers. Indomethacin and 2,4 diamino hydroxy pyrimidine pre-treated rats, but
not nabumetone, had increased intestinal permeability.
Conclusion:  The results suggest that the in vivo effects of indomethacin modulate the
mitochondrial respiratory chain directly at 1 h and 24 h through formation of nitric oxide. NO•
appears to play an important role in the late pathogenic stages of NSAID enteropathy and may be
the site for targeted treatment to reduce their toxicity.
Introduction
The major problem with the use of nonsteroidal anti-in-
flammatory drugs (NSAIDs) is the high prevalence of their
gastrointestinal toxicity [1]. Accordingly 40% of patients
have non-ulcer gastric lesions, 10–25% gastric ulcer and
65% NSAID enteropathy [2]. The development of safer
NSAIDs is dependent on knowledge of the pathogenesis
of damage. In general, two distinct phases (topical and
Published: 18 April 2002
BMC Gastroenterology 2002, 2:8
Received: 30 December 2001
Accepted: 18 April 2002
This article is available from: http://www.biomedcentral.com/1471-230X/2/8
© 2002 Somasundaram et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, 
provided this notice is preserved along with the article's original URL.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/8
Page 2 of 7
(page number not for citation purposes)
systemic) are suggested to be involved in the pathogenesis
of enteropathy [3–5]. The topical phase of damage may be
due to the effect of NSAIDs to uncouple mitochondrial
oxidative phosphorylation or inhibit electron transfer [4–
6] either of which would result in a decrease in cellular
ATP levels[7] and a disrupted intestinal barrier function.
Consequently, it is suggested, increased intestinal perme-
ability transforms the cellular damage into a tissue reac-
tion where inflammation and ulcers occur because of
mucosal exposure of luminal aggressive factors (such as
acid, pepsin, bile, pancreatic secretions and bacteria) and
the effects of decreased mucosal prostaglandins on the mi-
crovasculature.
In respect of early pathogenic events in the development
of NSAID damage it has been shown that uncoupling of
oxidative phosphorylation and inhibition of electron
transport occurs with all commonly available acidic-
NSAIDs. Our earlier studies indicate [8,9] that indometh-
acin, aspirin and naproxen uncouple mitochondrial oxi-
dative phosphorylation at concentration between 30 and
500 µM and inhibit the electron transport chain at higher
concentrations. The issue of inhibition of electron trans-
port by NSAIDs in the pathogenesis of damage and its
pathophysiological consequences is complicated by the
fact that nitric oxide (NO•), which plays a pathogenic role
in the damage, may bind to metalloproteins [Fe-S] of the
respiratory chain and by itself increase intestinal permea-
bility [10]. Thus NSAIDs may inhibit electron transport
directly or indirectly by induction of nitric oxide (NO•)
[11–16]. The aim of the current study was to assess and
discriminate between the direct and indirect effects of
NSAIDs on electron transport of the rat small intestine us-
ing electron paramagnetic resonance (EPR) spectroscopy.
Principle:Intestinal mitochondrial electron transfer sys-
tem plays a significant role in the pathogenesis of NSAID
enteropathy. In the mitochondria electron transfer occur
in the iron sulphur proteins arranged sequentially. Loss
(oxidation) and gain of electrons (reduction) in this iron
sulphur proteins can be visualized as a spectrum in the
EPR machine. It has been hypothesized that NSAID might
have an affinity towards these iron sulphur proteins and
alter the redox state.
Materials and methods
Experimental design
Electron paramagnetic studies
Male Sprague-Dawley rats (200–250 g) were used
throughout EPR studies. 12 rats received indomethacin 20
mg/kg, which is a commonly used dose to induce consist-
ent small intestinal damage in the rat (characterized by
mitochondrial damage on electron microscopy within an
hour,[17] neutrophil infiltration of mucosa on light mi-
croscopy at 3–5 hours and macroscopic lesions (ulcers) at
12–18 hours [18]); . A separate group of 12 rats received
the non-acidic pro-NSAID nabumetone (500 mg/kg). The
maximum human doses of indomethacin in man is 150
mg/day and 2000 mg for nabumetone so that the equiva-
lent doses given here are at least 8 and 17 fold greater than
the recommended doses for indomethacin and nabume-
tone, respectively and many times higher than this re-
quired for anti-inflammatory activity.
Nabumetone is unusual amongst NSAIDs in that it does
not produce any small intestinal lesions in the rat, pre-
sumably because it is non-acidic (and hence not a proton
translocator or an inhibitor of the electron transport
chain) and its active component 6-methoxy-2-naphthyl-
acetic acid (6-MNA) is not subjected to excretion in bile
[9,19]. Incorporation of nabumetone therefore allows as-
sessment of the systemic effects of cyclooxygenase inhibi-
tion in isolation from its topical effects.
In separate studies the inhibitor of inducible nitric oxide
synthase, 2,4 diamino-6-hydroxy pyrimidine (DAHP; a
potent inhibitor of tetrahydrobiopterin synthesis, which
is a cofactor for the inducible nitric oxide synthase activi-
ty) 1.0 gm /kg b.w. was administered to 12 rats intra-peri-
tonealy 1 hr before indomethacin (20 mg/kg) gavages.
Preparation of drugs: Indomethacin and nabumetone
were dissolved in 10% dimethyl sulfoxide and then dilut-
ed to the final concentration of 5% and administered oral-
ly by a gastric gavage without anaesthesia. Control rats
were received the same volume and concentrations of
dimethylsulfoxide.
Intestinal permeability assessment
Rats, 12 in each group, were fasted overnight and received
solvent, 20 mg/kg indomethacin or nabumetone (500
mg/kg) by gavage. 12 rats received DAHP i.p. (1.0 g/kg) 1
hr before indomethacin (20 mg/kg). Rats were fed 2 hrs
later and fasted the following night. Twenty hrs after
NSAID administration these rats received the intestinal
permeability marker 51Cr- EDTA (10 uCi / rat in 0.5 ml
followed, by 0.5 ml water) by gavage and were placed in
metabolic cages. Urine was collected for 5 hrs and the
samples were counted in Wallace 1842-LKB gamma coun-
ter with appropriate standard. The percentage of the orally
administered radioactive chromium excreted in urine was
calculated.
Morphological assessment
20 hours after administration of these drugs rat small in-
testinal mucosa (n = 12) was exposed by a cut through the
anti- mesenteric side and laid out each group on a piece of
cork for assessment of macroscopic damage.[24] The as-
sessments were carried out by an independent person un-
aware of the drug treatments. An ulcer count was made toBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/8
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distinguish between pointed (<5 mm) and longitudinal
(>5 mm) ulcers.
Isolation of mitochondrial fractions
Bovine heart mitochondria were isolated based on a mod-
ification of Schneider & Hogeboom method (1950) [20],
diluted to 10 mg protein/ml and sonicated in 3 ml aliq-
uots on ice with eight 15 sec bursts, interrupted by 15 sec
intervals, at 18 amps using a micro tip probe. The sonicat-
ed suspension was centrifuged at 26,000 g for 10 min at
4'C. The supernatant fraction was centrifuged at 130,000
g for 1 hr, and the sub mitochondrial particles pellet resus-
pended for EPR analysis after checking the purity of this
fraction (by studying the electron transfer reactions using
potassium ferricyanide as an electron acceptor and succi-
nate as a substrate). This experiment was repeated for
three times at various intervals. It has been attempted to
isolate submitochondrial fraction of jejunal mitochondria
from rats. In most of the cases we could not able to
achieve a good yield of submitochodrial particles. Hence
we used bovine heart miotochondria to understand the
basic phenomena of NSAID binding sites.
EPR spectroscopy
1 hr and 24 hr after administration of the drugs, the ani-
mals were anaesthetized (Hypnovil and Hypnorm) and
underwent laparotomy. Segments of jejunum 10 cm distal
to the ligament of Trietz were snap frozen with liquid ni-
trogen and stored for a maximum of 2 weeks. Samples
were thawed and homogenized in 10% (w/v) of sucrose
(74 mM), mannitol (225 mM), homogenising buffer
(0.25 M) containing EDTA (1 mM), 5 mg/ml BSA solution
in MOPS-NaOH buffer (10 mM), pH 7.4, by 15 strokes of
a tight fitting teflon pestle. 100 ul samples (1 mg protein)
were placed in quartz EPR tubes (3 mm-internal diame-
ter) and immediately frozen in liquid nitrogen. X-band
EPR spectra were recorded on a Bruker ESP 300 spectrom-
eter fitted with an Oxford Instruments ESR900 liquid he-
lium flow cryostat at 8 K and 20 K or 30 K. The effect of 10
ul of 250 mM indomethacin added to 90 ul (1 mg pro-
tein) of submitochondrial particles in a quartz EPR tube
and read the EPR spectra at 8 K was assessed with appro-
priate controls. Spectra were an average of six scans and
normalized for direct comparison. The experiments were
repeated for three different times with separate group of
animals.
EPR conditions: Temperature 8 K or 20 K or 30 K: micro-
wave power 20 mW, microwave frequency 9.35 GHz,
modulation frequency 100 Khs, modulation amplitude 1
mT, receiver gain 1.25 ×  105, time constant 0.33 sec,
sweep time 2.4 mT/sec. Spectra displayed are average of
6–8 scans.
Statistics
Data are presented as mean ±SEM. Statistical comparison
between groups were made by Mann-Whitney U test.
Results
Morphology
No macroscopic changes were observed in controls or
with indomethacin and nabumetone 1 hr after drug ad-
ministration. At 24 hr the indomethacin-treated group ex-
hibited severe intestinal ulceration (pointed ulcers: mean
= 55 ± 10, longitudinal ulcers: mean = 15 ± 9). No ulcers
were seen in controls, nabumetone or DAHP treated in-
domethacin gavaged rats. [Table 1]
Intestinal permeability
Controls excreted 2.3 ± 1.2% of the orally administered
51Cr-EDTA in 5 h urine. Intestinal permeability was not
significantly (p > 0.5) increased following nabumetone
(mean 2.7 ± 1.5%). Indomethacin treated rats and those
pre-treated with DAHP (+indomethacin) had significantly
increased (p < 0.01) intestinal permeability to 51Cr-EDTA
(10.5 ± 2.5% and 11.5 ± 1.8% respectively) [Table 1]
Table 1: The ulcerogenic and intestinal permeability (51Cr-EDTA excretion) effect of DMSO (Control), indomethacin, DAHP pretreat-
ed indomethacin and nabumetone gavaged rat small intestine.
Group Treatment Pointed ulcers Longitudinal ulcers % Excretion of 51Cr-EDTA in 
Urine
1 Control(DMSO) 0 0 2.3 ± 1.2
2 Indomethacin 55 ± 10 15 ± 9 * 10.5 ± 2.5
3 DAHP pretreated indomethacin 0 0 * 11.5 ± 0.8
4 Nabumetone 0 0 2.7 ± 1.5
* P < 0.01BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/8
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EPR spectroscopic study of NSAIDs on sub-mitochondrial 
particles
At 8 K, the EPR spectrum of bovine heart sub mitochon-
drial particles administered DMSO alone (Fig. 1) dis-
played a prominent resonance at g ~ 2.014. This signal
was only observed in the oxidized state at temperatures
below 25 K, and is characteristic of the [3Fe-4S]ox cluster
of mitochondrial Complex II Centre S3. Extra features at g
~ 2.04, 1.99 are present, and are assigned to interactions
between ubisemiquinone radicals [23].
Indomethacin but not nabumetone or DAHP added to
the sub mitchondrial particles significantly decreased the
intensity of the latter featrures (Fig. 1) (g ~ 2.04 and 1.99)
suggesting formation of radical species which is indicative
of binding of indomethacin to and the inhibition of the
respiratory chain direct to this site.
EPR spectroscopic studies of NSAIDs on rat jejunal ho-
mogenates
At 20 K, control rat intestinal homogenates also displayed
a signal indicative of Centre S3, albeit weaker (Fig. 2a). A
similar signal could be detected 1 hr and 24 hr after
nabumetone administration. [Fig. 2b and Fig 3b)] How-
ever, with indomethacin the [3Fe-4S]ox signal intensity
was decreased at 1 hr, and by 24 hr the EPR spectrum of
intestinal homogenates displayed a prominent new reso-
nance centered at g ~ 2.0, with a peak at g ~ 2.07 and a tri-
plet splitting centered at g ~ 2.01, indicative of nitrosyl-
haem (haem-NO) formation. [Fig. 2c and Fig 3c]. DAHP
pre treated indomethacin group significantly decreased
the haem-NO intensity at 24 hr after administration [Fig.
4], thereby allowing detection of the Centre S3 signal at 8
K [Fig. 5]. DAHP pretreated indomethacin group dis-
played the similar signals at 1 hr, when compared to in-
domethacin alone treated group [.i.e., decreased in the
[3Fe-4S]ox signal at 1 hr, Data not shown]. The haem-NO
signal observed in Fig. 3c shows a splitting of A (14N) ~
330 mT [Fig. 4 at 30 K]. Similar signals have been ob-
served for the NO-adducts of type II haem proteins such
as cytochrome c oxidase and hemoglobin [21] Figure 3 ex-
plains the unique features of nitrosyl signals (g ~ 2.04) at
20 K only in indomethacin treated group and not in the
DMSO-control or nabumetone group. Figure 4 displays
the differential pattern of the nitrosyl signals (i)-(ii) at
30K after 24 hr of indomethacin (i) and DAHP treated in-
domethacin group(ii) when compare to the DMSO-con-
trol (iii) spectra. This prominent nitrosyl signals at 30 K is
the characteristics of the free radical species and tempera-
ture sensitive when compare to the signals at 8 K, dis-
played in Figure 5. In indomethacin alone treated group
(Figure 4) this broad signal displayed a peak at g ~ 2.04, a
distinct trough at g ~ 1.98 and complex splitting (triplet)
centered at g ~ 2.01 at temperature above 25 K, indicative
of haem-nitrosyl formation.[21]
Discussion
The present results show that indomethacin treated rats
and not those pretreated with DAHP exhibited small in-
testinal ulcers at 20 hr. There was increased intestinal per-
meability and an early (1 hr) direct effect of indomethacin
consistent with inhibition of electron transport in both
groups but only the indomethacin treated group exhbited
a haem-nitrosyl complex EPR signal at g ~ 2.07. Thus the
present result suggests that the nitric oxide radical may
play a role in the development of indomethacin-induced
ulcers. Within the current pathogenic framework [5]
where it is proposed that NSAIDs affect mitochondrial en-
ergy metabolism leading to increased intestinal permea-
bility and where the micro vascular alterations, caused by
changes in prostaglandin and nitric oxide metabolism are
the driving force in the development of ulcers. The in-
volvement of nitric oxide occurs temporarily later or at a
different pathophysiological step than the intestinal per-
meability changes. The non-acidic Pro-NSAID nabume-
tone caused no intestinal lesion as previously described
[22] and was not associated with changes in the EPR spec-
tra, despite being effective inhibitors of cyclooxygenase
and associated with decreased mucosal prostaglandins at
much smaller doses[22]. These findings are consistent
Figure 1
The EPR spectra of (I) DMSO-control and (ii) indomethacin
(25 mM final concentration) treated bovine heart submito-
chondrial particles at 8 K.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/8
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with previous in vitro and in vivo work showing that
nabumetone itself does not alter mitochondrial energy
metabolism whilst its active metabolite 6MNA does.
However it would appear that as 6MNA is formed follow-
ing absorption of nabumetone, over 99% of 6MNA is pro-
tein bound within the circulation and it is not excreted in
bile, insufficient intestinal concentrations of 6MNA are
achieved to affect enterocyte mitochondria.
NSAIDs uncouple oxidative phosphorylation at 30–500
uM and inhibit mitochondrial electron transport at higher
concentration in vitro [8] The relative importance and
contribution of uncoupling and inhibition in the patho-
genesis of the "topical" Phase of damage is uncertain, but
either mechanism would lead to decreased cellular ATP
and hence increased intestinal permeability. In this study
we assessed the characteristics of NSAID modulation of
electron transport in vivo in rats and in vitro in bovine
heart submitochondrial particles. The EPR spectra ob-
served at 1 hr would appear to be the result of a direct ef-
fect of indomethacin on electron transport unrelated to
NO', since pretreatment with DAHP did not alter the in-
domethacin spectra. The EPR spectra at 24 hr post in-
domethacin [Fig. 2B (c)] indicated formation of NO'
which is further substantiated by abolition of this signal
when rats were pretreated with DAHP [Fig. 3].
The activity of iNOS is controlled mainly at the levels of
transcription and translation and is dependent on the
availability of co-factors including tetrahydrobiopterin
(BH4). A recent study has demonstrated that inhibition of
BH4 synthesis reduces NO• production in vivo in experi-
mental endotoxic shock[12]. The same strategy of inhibi-
tion of BH4 synthesis has been applied in this present
Figure 2
The EPR spectra of rat jejunal homogenates at 20 K after 1
hr oral gavage of (a) DMSO, (b) nabumetone (500 mg / kg
b.wt) and (c) indomethacin (20 mg/kg b.wt)
Figure 3
The EPR spectra of rat jejunal homogenates at 20 K after 24
hr oral gavage of (a) DMSO, (b) nabumetone (500 mg / kg
b.wt) and (c) indomethacin (20 mg/kg b.wt)BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/8
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attempt to investigate ulcer formation in indomethacin-
induced intestinal ulcer. We found that injection of DAHP
an inhibitor of BH4 synthesis prevented ulcer formation,
although it did not alter the increased intestinal permea-
bility induced by indomethacin. This suggests that it does
not modulate the direct biochemical actions of NSAIDs
but interferes at a later stage in the pathogenesis of the
damage. One possibility is that DAHP suppresses NO for-
mation in neutrophils (iNOS), which infiltrate the muco-
sa in response to increased intestinal permeability. In
order to study the specificity of the nitric oxide synthesis
the experiments with N(G)-nitro-L-argenine methyl ester
(L-NAME-10 mg /kg b wt s.c 1 hr prior to indomethacin)
was carried out to prevent nitrosyl signals and ulcers in-
duced by indomethacin. We did not find the inhibition of
intestinal ulcers.
This observation is further confirmed by the recent reports
[25] stating the worsening effect of L-NAME (5–20 mg/kg)
on these lesions was dose-dependently observed in asso-
ciation with further enhancement of the bacterial translo-
cation and intestinal hypermotility following
indomethacin. Thus it has been concluded that this effect
may be due to the nonspecific inhibition of L-NAME and
it is not a specific inhibitor of iNOS cofactor biopterin
complex and hence excluded from EPR study.
Conclusions
In summary, it is interesting that in spite of the increased
intestinal permeability, there were no ulcers seen in the
DAHP treated group indicating that inhibition of induci-
ble nitric oxide synthase (in neutrophils and macrophag-
es) could become a targeted therapeutic approach to
reduce the intestinal toxicity of NSAIDs, and nabumetone
is comparatively safer with neither inducing ulcer nor for-
mation of nitrosyl complex in this study.
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